Market revenue in 2023 | USD 2,528.6 million |
Market revenue in 2030 | USD 8,314.7 million |
Growth rate | 18.5% (CAGR from 2023 to 2030) |
Largest segment | Functional genomics |
Fastest growing segment | Pathway Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery |
Key market players worldwide | Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genomics market will help companies and investors design strategic landscapes.
Functional genomics was the largest segment with a revenue share of 32.24% in 2023. Horizon Databook has segmented the China genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2018 to 2030.
The growing biotechnological and pharmaceutical sector has a direct positive impact on the growth of the genomics market. In addition, with the development of these industries, there is increased biotechnological development in China, which has led to an increase in the market share of genomics in China.
Improving healthcare infrastructure and growing healthcare expenditure by pharmaceutical companies and the government is expected to drive the genomics market. For instance, the Chinese government launched an initiative of Precision Medicine that could amount to around USD 9 billion over the next 15 years.
China has one of the fastest-growing and most advanced genomics markets. In 2020, the country’s genetic testing companies raised approximately USD 3 billion in financing. NGS can improve human health by enabling early diagnosis of rare diseases, more pathogen monitoring, and improved outcomes for cancer patients.
Horizon Databook provides a detailed overview of country-level data and insights on the China genomics market , including forecasts for subscribers. This country databook contains high-level insights into China genomics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account